JP2024502253A - 胃がんの防止及び早期検出のためのバイオマーカーシグネチャー - Google Patents

胃がんの防止及び早期検出のためのバイオマーカーシグネチャー Download PDF

Info

Publication number
JP2024502253A
JP2024502253A JP2023537677A JP2023537677A JP2024502253A JP 2024502253 A JP2024502253 A JP 2024502253A JP 2023537677 A JP2023537677 A JP 2023537677A JP 2023537677 A JP2023537677 A JP 2023537677A JP 2024502253 A JP2024502253 A JP 2024502253A
Authority
JP
Japan
Prior art keywords
levels
biomarkers
gastric cancer
lep
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502253A5 (https=
Inventor
エリエッテ・カミーユ・トアティ
ヴァレリ・ミシェル
ドミニク・ラマルク
クェンティン・ジャイ・ジャネット
ティボー・デューシュ
マリエッテ・マトンド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of JP2024502253A publication Critical patent/JP2024502253A/ja
Publication of JP2024502253A5 publication Critical patent/JP2024502253A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/20—ICT specially adapted for the handling or processing of medical references relating to practices or guidelines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioethics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023537677A 2020-12-21 2021-12-21 胃がんの防止及び早期検出のためのバイオマーカーシグネチャー Pending JP2024502253A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306649.3 2020-12-21
EP20306649 2020-12-21
PCT/EP2021/087155 WO2022136472A1 (en) 2020-12-21 2021-12-21 Biomarkers signature(s) for the prevention and early detection of gastric cancer

Publications (2)

Publication Number Publication Date
JP2024502253A true JP2024502253A (ja) 2024-01-18
JP2024502253A5 JP2024502253A5 (https=) 2024-12-19

Family

ID=74184396

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537677A Pending JP2024502253A (ja) 2020-12-21 2021-12-21 胃がんの防止及び早期検出のためのバイオマーカーシグネチャー

Country Status (7)

Country Link
US (1) US20240053343A1 (https=)
EP (1) EP4263872A1 (https=)
JP (1) JP2024502253A (https=)
KR (1) KR20230124671A (https=)
CN (1) CN116867911A (https=)
CA (1) CA3202252A1 (https=)
WO (1) WO2022136472A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4497005A1 (en) * 2022-03-23 2025-01-29 Serum Detect, Inc. Biomarker signatures indicative of early stages of cancer
CN116500276A (zh) * 2023-04-26 2023-07-28 苏州大学附属儿童医院 一种usf2表达量的检测方法及应用
CN118483437B (zh) * 2024-07-15 2024-10-18 济南市中心医院 区分普通高血压与难治性高血压的生物标志物及其应用
CN118645252B (zh) * 2024-08-16 2025-01-28 杭州和壹基因科技有限公司 基于深度学习的疾病风险评估方法及系统

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009099005A1 (ja) * 2008-02-06 2009-08-13 Ajinomoto Co., Inc. 胃癌の評価方法、ならびに胃癌評価装置、胃癌評価方法、胃癌評価システム、胃癌評価プログラムおよび記録媒体
WO2012167112A2 (en) * 2011-06-01 2012-12-06 Illumina, Inc. Gastric cancer biomarkers
JP2015505370A (ja) * 2012-01-20 2015-02-19 アデレード リサーチ アンド イノベイション ピーティーワイ エルティーディーＡｄｅｌａｉｄｅ Ｒｅｓｅａｒｃｈ ＆ Ｉｎｎｏｖａｔｉｏｎ Ｐｔｙ Ｌｔｄ 胃癌のバイオマーカー及びその使用
CN105572354A (zh) * 2014-10-17 2016-05-11 广州瑞博奥生物科技有限公司 一种检测早期胃癌的抗体芯片试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2857520A1 (en) 2013-10-03 2015-04-08 Institut Pasteur Method for in vitro investigating mitochondrial dna levels in a biological sample, kits and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009099005A1 (ja) * 2008-02-06 2009-08-13 Ajinomoto Co., Inc. 胃癌の評価方法、ならびに胃癌評価装置、胃癌評価方法、胃癌評価システム、胃癌評価プログラムおよび記録媒体
WO2012167112A2 (en) * 2011-06-01 2012-12-06 Illumina, Inc. Gastric cancer biomarkers
JP2015505370A (ja) * 2012-01-20 2015-02-19 アデレード リサーチ アンド イノベイション ピーティーワイ エルティーディーＡｄｅｌａｉｄｅ Ｒｅｓｅａｒｃｈ ＆ Ｉｎｎｏｖａｔｉｏｎ Ｐｔｙ Ｌｔｄ 胃癌のバイオマーカー及びその使用
CN105572354A (zh) * 2014-10-17 2016-05-11 广州瑞博奥生物科技有限公司 一种检测早期胃癌的抗体芯片试剂盒

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JULIEN FERNANDES ET AL.: ""Circulating Mitochondrial DNA Level, a Noninvasive Biomarker for the Early Detection of Gastric Ca", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, vol. 23, no. 11, JPN6025045754, 1 November 2014 (2014-11-01), pages 2430 - 2438, ISSN: 0005728377 *
LISETTE G. CAPELLE ET AL.: ""Serum Levels of Leptin As Marker For Patients At High Risk of Gastric Cancer"", HELICOBACTER, vol. 14, no. 6, JPN6025045761, 4 November 2009 (2009-11-04), pages 596 - 604, ISSN: 0005728375 *
MEIRA EPPLEIN ET AL.: ""Circulating cytokines and gastric cancer risk"", CANCER CAUSES CONTROL, vol. 24, no. 12, JPN6025045759, 20 September 2013 (2013-09-20), pages 2245 - 2250, ISSN: 0005728376 *

Also Published As

Publication number Publication date
KR20230124671A (ko) 2023-08-25
US20240053343A1 (en) 2024-02-15
CA3202252A1 (en) 2022-06-30
CN116867911A (zh) 2023-10-10
EP4263872A1 (en) 2023-10-25
WO2022136472A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
US12060617B2 (en) Marker genes for prostate cancer classification
JP2024502253A (ja) 胃がんの防止及び早期検出のためのバイオマーカーシグネチャー
AU2006236621B2 (en) Diagnostic for lung disorders using class prediction
US9939442B2 (en) Salivary biomarkers for gastric cancer detection
EP4045912A1 (en) Apparatuses and methods for detection of pancreatic cancer
CN105755112A (zh) 结肠直肠癌的诊断
WO2010151789A1 (en) Salivary transcriptomic and microbial biomarkers for pancreatic cancer
CN110229899B (zh) 用于结直肠癌早期诊断或预后预测的血浆标记物组合
AU2020252417B2 (en) Salivary biomarkers for the detection of epidermoid cancer of the head and neck
CN111763736B (zh) 用于诊断甲状腺乳头状癌淋巴结转移的液体活检试剂盒
CN113943815A (zh) 基于alk的生物标志物组及其应用
JP2023531860A (ja) 肺癌検出用バイオマーカー
RU2813669C1 (ru) Способ неинвазивной диагностики рака мочевого пузыря на основе выявления опухолевой днк в биологических жидкостях и набор реагентов для его осуществления
JP6099109B2 (ja) 新規肺癌マーカー（ｌｉｐｈ）
EP2607494A1 (en) Biomarkers for lung cancer risk assessment
AU2018100578A4 (en) Method for detection & diagnosis of oral cancer in a sample
CN119193833A (zh) Sctag在食管癌的早期诊断、预后评估和复发预警中的应用
AU2023246912A1 (en) A method of predicting risk of an aggressive or recurrent cancer
CN119570928A (zh) 用于结直肠癌诊断和预后预测的lncRNA组合
CN116219007A (zh) 检测结直肠癌的生物标志物组及其应用
CN114015778A (zh) 预测肺癌的生物标志物组
HK1197686B (en) Marker genes for prostate cancer classification
HK1197686A (en) Marker genes for prostate cancer classification

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241211

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260421